Recommendation of the President – Tremfya (guselkumab)
On 17 December 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 196/2025 on the reimbursement of the medicinal product Tremfya (guselkumab) under drug program B.32. “Treatment of patients with Crohn’s disease (ICD-10: K50)”